Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults ...
WHEAT RIDGE, CO / ACCESS Newswire / March 27, 2026 / Lifeloc Technologies, Inc. (OTC:LCTC), a global leader in the ...
Acquisition integrates patent-pending algorithms and data insight engine into PetaSight’s operating system so pharmaceutical ...
Customer-first initiative helps specialty pharmacies and e-commerce leaders keep pace with the rapidly evolving GLP-1 ...
March 26, 2026] A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion is no ...
Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic ...
Market OverviewThe global MedTech Contract Manufacturing Organization (CMO) market is witnessing robust growth, expanding at ...
Homecare Feeding, Aging Population, and Technological Innovation Driving Global GrowthThe nasogastric intubation market is ...
The European Investment Bank (EIB) has waived the put option attached to the warrants granted in connection with the €40 ...
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CMLMerck to hold investor call at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results